Skip Navigation



BJA Advance Access published online on September 2, 2005

British Journal of Anaesthesia, doi:10.1093/bja/aei225
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
95/5/648    most recent
aei225v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alhashemi, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alhashemi, J. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Board of Management and Trustees of the British Journal of Anaesthesia 2005. All rights reserved. For Permissions, please e-mail: journal.permissions@oxfordjournals.org
Accepted July 11, 2005

Case Report

Treatment of cardiogenic shock with levosimendan in combination with {beta}-adrenergic antagonists

J. A. Alhashemi 1*

1 Department of Anesthesia and Critical Care, King Abdulaziz University, King Abdulaziz University Hospital, PO Box 31648, Jeddah 21418, Saudi Arabia

* To whom correspondence should be addressed.
J. A. Alhashemi, E-mail: jalhashemi{at}kau.edu.sa


   Abstract

Levosimendan, a calcium sensitizer, was used in combination with {beta}-adrenergic antagonists in a man aged 56 yr with cardiogenic shock, complicating acute myocardial infarction, who developed severe tachycardia after dobutamine administration. The patient's trachea was intubated, his lungs were ventilated, and he was started on dopamine 5 µg kg-1 min-1 and dobutamine 5 µg kg-1 min-1, titrated to a mean arterial pressure ≥65 mm Hg. He progressively became tachycardiac (>120 beats min-1) with a cardiac index (CI) of 1.4 litre min-1 m-2 despite adequate preload. Levosimendan 6 µg kg-1 was administered intravenously over 10 min followed by a continuous infusion of 0.2 µg kg-1 min-1 for 24 h. Within 30 min, the patient's CI increased to 2.2 litre min-1 m-2, but the heart rate (HR) also increased from 142 to 155 beats min-1. Esmolol 1 mg kg-1 i.v. was administered with a consequent transient decrease in HR to 110 beats min-1 without adverse haemodynamic effects; however, HR increased again shortly afterwards. Carvedilol 3.125 mg orally twice a day was then administered, and the dose was increased to 6.25 mg orally twice daily on the following day. Subsequently, HR decreased over time and both catecholamines were discontinued 14 h after starting levosimendan infusion. The trachea was extubated within 20 h and the patient was discharged to the ward on day 4 after admission. In conclusion, levosimendan in combination with a {beta}-adrenergic antagonist may have beneficial effects in patients with cardiogenic shock who exhibit tachycardia in response to inotropic agents.

Keywords: complications, myocardial infarction; heart arrhythmia, tachycardia; heart, dobutamine; heart, esmolol; pharmacology, agonists adrenergic.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Intensive Care MedHome page
M. W. Dunser and W. R. Hasibeder
Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress
J Intensive Care Med, September 1, 2009; 24(5): 293 - 316.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.